Other combinations, for instance pembrolizumab plus ramucirumab, have been reported to have manageable safety profile and signs of activity in other tumour types such as biliary tract cancer, NSCLC, gastroesophageal cancer, or urothelial carcinomas.31,32 Inhibition of angiogenesis-mediated immune suppression with the anti-Ang-2 therapy trebananib is under exploration in combination with pembrolizumab.33 Based on the available evidence, the effect of LY3127804 combined with ICIs should be explored in further studies. Here, ANGPT2 is linked to biliary tract cancer.